Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (Argenta)

AIDS

Volumn 16, Issue 3, 2002, Pages 369-379

  Cingolani, Antonella ^a   Antinori, Andrea ^a   Rizzo, Maria Gabriella ^a   Murri, Rita ^a   Ammassari, Adriana ^a   Baldini, Francesco ^a   Di Giambenedetto, Simona ^a   Cauda, Roberto ^a   De Luca, Andrea ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Adherence; Antiretroviral therapy; Drug resistance; Genotypic resistance; Salvage therapy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC RESISTANCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PATIENT COMPLIANCE; RNA, VIRAL; TREATMENT FAILURE;

EID: 0037083803     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200202150-00008     Document Type: Article

References (32)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
3. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
4. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
5. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
6. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
7. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt study
8. Antiretroviral drug resistance testing in adult HIV-1 infection
9. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society - USA Panel
10. Human immunodeficiency virus reverse transcriptase and protease sequence database
11. Incidence and impact of resistance against approved antiretroviral drugs
12. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy
13. Baseline HIV drug resistance profile predicts response to ritonavir/saquinavir protease inhibitors therapy in a community setting
14. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
15. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
16. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort study
17. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315. ACTG protocol 315 team
18. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection
19. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled study
20. A randomized study of antiretroviral management based on plasma genotypic resistance testing in patients failing therapy
21. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: A randomized trial (NARVAL, ANRS 088)
22. Utility of HIV genotyping and clinical expert advice - The Havana trial
23. Patient-reported nonadherence to HAART is related to protease inhibitors levels
24. Factors associated with the successful modification of antiretroviral therapy
25. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
26. The rabbit study: Ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients
27. Clinical utility of testing human immunodeficiency virus for drug resistance
28. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial. Italy, The Netherlands, Canada and Australia study
29. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group
30. Protease inhibitors. Resistance, cross-resistance, fitness and the choice of initial and salvage therapies
31. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
32. Prediction of treatment outcomes by different interpretation systems (IS) for baseline genotypic resistance in a cohort of patients on salvage HIV therapy